Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

49.08USD
20 Sep 2017
Change (% chg)

-- (--)
Prev Close
$49.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,466,309
52-wk High
$50.24
52-wk Low
$36.81

Latest Key Developments (Source: Significant Developments)

Sanofi strengthens relationship with Evidation Health
Tuesday, 1 Aug 2017 08:11am EDT 

Aug 1 (Reuters) - SANOFI ::SAID ON MONDAY IT STRENGTHENS RELATIONSHIP WITH EVIDATION HEALTH.  Full Article

Lexicon Pharmaceuticals reports opt-in decision for U.S. co-promotion of sotagliflozin with Sanofi in type 1 diabetes
Monday, 31 Jul 2017 06:01pm EDT 

July 31 (Reuters) - Lexicon Pharmaceuticals Inc ::Lexicon Pharmaceuticals announces opt-in decision for u.s. Co-Promotion of sotagliflozin with Sanofi in type 1 diabetes.Lexicon Pharmaceuticals - says ‍Sanofi intends to file applications in first half of 2018 for EU and U.S. Regulatory reviews of sotagliflozin​.Lexicon Pharmaceuticals- ‍opt-in decision based on positive data from 3 phase 3 studies, intandem1, intandem2, intandem3​.  Full Article

Sanofi raises FY 2017 business EPS guidance to broadly stable at CER
Monday, 31 Jul 2017 07:30am EDT 

July 31 (Reuters) - Sanofi Sa :Sanofi raises FY 2017 business EPS guidance to broadly stable at CER.  Full Article

EU Medicines Agency recommends approval of Novartis' leukaemia drug
Friday, 21 Jul 2017 07:37am EDT 

July 21 (Reuters) - EU Medicines Agency: :EU Medicines Agency recommendations For July 2017.EU Medicines Agency recommends approval of Pfizer Inc and Merck KGAA Avelumab drug for cell carcinoma‍​.EU Medicines Agency recommends approval of Sanofi and Regeneron Dupixent drug for severe eczema.EU Medicines Agency recommends approval Of Roche Tecentriq drug for drug for bladder and lung cancer‍​.EU Medicines Agency recommends approval Of Advanced Accelerator Applications Lutathera drug for gastroenteropancreatic neuroendocrine tumours.EU Medicines Agency recommends against approval of Nektar Therapeutics and Daiichi Sankyo Onzeald drug for breast cancer.EU Medicines Agency recommends approval of Novartis Rydapt drug for leukaemia.  Full Article

Ablynx and Sanofi enter into a strategic collaboration
Thursday, 20 Jul 2017 01:13am EDT 

July 20 (Reuters) - ABLYNX NV : :ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES.ABLYNX NV - ‍COLLABORATION GIVES SANOFI ACCESS TO CERTAIN NANOBODIES IN ABLYNX'S EXISTING PORTFOLIO​.ABLYNX NV - ‍SANOFI GAINS EXCLUSIVE GLOBAL RIGHTS TO CERTAIN MULTI-SPECIFIC NANOBODIES AGAINST SELECTED TARGETS​.ABLYNX NV - ‍FINANCIAL TERMS INCLUDE AN UPFRONT PAYMENT OF EUR 23 MILLION TO ABLYNX​.ABLYNX NV - ‍ABLYNX WILL RECEIVE RESEARCH FUNDING, ESTIMATED TO AMOUNT TO EUR 8 MILLION FOR INITIALLY SELECTED TARGETS​.  Full Article

Emergent Biosolutions updates terms of termination of agreement related to acquisition of Sanofi's acam2000 business
Friday, 14 Jul 2017 07:28am EDT 

July 14 (Reuters) - Emergent Biosolutions Inc ::Emergent Biosolutions updates on terms of any termination of agreement related to acquisition of acam2000 business from Sanofi.Emergent Biosolutions - agreement will become void and have no effect, except that certain specified obligations of Emergent and Sanofi shall survive.Emergent Biosolutions - certain specified obligations of both parties shall survive including those concerning confidentiality and public announcements.  Full Article

Emergent BioSolutions to acquire ACAM2000 business from Sanofi
Friday, 14 Jul 2017 07:00am EDT 

July 14 (Reuters) - Emergent Biosolutions Inc :Emergent biosolutions to acquire acam2000® business from sanofi.Emergent biosolutions to acquire acam2000® business from sanofi.Emergent biosolutions inc - deal for ‍all-cash consideration of $97.5 million upfront​.Emergent biosolutions inc - deal for all-cash transaction with a total value of up to $125 million.Emergent biosolutions-deal includes ‍all-cash consideration of $97.5 million upfront ​.Emergent biosolutions-deal also includes up to $27.5 million in near-term contingent regulatory & manufacturing-related milestones​.Emergent - deal expected to be accretive beginning with anticipated product deliveries in 2018 following fda licensure of u.s.-based manufacturing facility​.Emergent biosolutions-‍emergent will assume responsibility for existing 10-year cdc contract, which will expire and be up for renewal or extension in 2018​.Emergent biosolutions inc- intends to negotiate a follow-on, multi-year contract with u.s. Government to ensure continued supply of acam2000 to sns​.Emergent - ‍upon closing, co will assume all responsibilities under cdc contract valued at up to approximately $160 million​.Emergent biosolutions inc - anticipates product deliveries will resume in 2018, following expected fda licensure of u.s.-based manufacturing facility​.Emergent biosolutions - ‍expect deal to "meaningfully" contribute to revenue growth in 2018 & advance efforts towards achieving $1 billion in revenue by 2020​.  Full Article

Alnylam Pharmaceuticals and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study
Monday, 10 Jul 2017 09:30am EDT 

July 10 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study with investigational RNAI therapeutic Fitusiran in patients with hemophilia A and B with or without inhibitors.Says majority of adverse events were mild/moderate in severity, with most common ae's consisting transient, mild injection site reactions.Says with up to 20 months of dosing, fitusiran safety and tolerability profile remains encouraging in the study.Says there was one discontinuation in study due to AE, an asymptomatic alanine aminotransferase elevation in patient with hcv infection.Says expect initial results of atlas phase 3 program in mid-to-late 2019.  Full Article

Lexicon Pharmaceuticals amends collaboration and license agreement
Friday, 7 Jul 2017 09:34am EDT 

July 7 (Reuters) - Lexicon Pharmaceuticals Inc ::Lexicon Pharmaceuticals - on july 1, 2017, entered into an amendment to collaboration and license agreement with Sanofi-Aventis Deutschland GMBH.Lexicon Pharmaceuticals Inc - remain eligible to receive an aggregate of $210 million upon achievement of amended clinical development milestones.Lexicon Pharmaceuticals - remain eligible to receive up to $220 million upon achievement of specified regulatory milestones.Lexicon Pharmaceuticals - remain eligible to receive up to $990 million upon the achievement of specified commercial milestones.Lexicon Pharmaceuticals - under amended milestones, eligible to receive up to $110 million upon achievement of 4 milestones.Lexicon Pharma-pursuant to amendment, co eligible to $100 million upon achievement of milestone based on results of studies in type 2 diabetes patients.  Full Article

Alnylam and Sanofi Genzyme initiate ATLAS Phase 3 program with investigational RNAi therapeutic fitusiran
Friday, 7 Jul 2017 07:30am EDT 

July 7 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam and Sanofi Genzyme initiate ATLAS phase 3 program with investigational RNAi therapeutic fitusiran.Says expect top-line data from the ATLAS trials in mid-to-late 2019.says ATLAS studies are expected to enroll about 250 patients across 3 separate trials conducted around the world.Says ATLAS to evaluate safety and efficacy of Fitusiran across broad spectrum of patients living with hemophilia.  Full Article

BRIEF-Alnylam's genetic disease drug meets main goal in phase 3 study

* Sanofi and Alnylam report positive topline results from APOLLO phase 3 study of patisiran in Hereditary ATTR (HATTR) amyloidosis patients with polyneuropathy